Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study

Trial Profile

Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs Sparsentan (Primary) ; Irbesartan
  • Indications Focal segmental glomerulosclerosis
  • Focus Adverse reactions; Proof of concept; Registrational; Therapeutic Use
  • Acronyms DUET
  • Sponsors Retrophin
  • Most Recent Events

    • 07 Nov 2017 Results of pharmacokinetics and pharmacodynamics analyses from this trial presented at the ASN Kidney Week 2017, according to a Retrophin Inc. media release.
    • 07 Nov 2017 Data from the ongoing open-label extension of this trial presented at the ASN Kidney Week 2017, according to a Retrophin Inc. media release.
    • 03 Nov 2017 Results published in a Retrophin Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top